Search results
Showing 1096 to 1110 of 8244 results
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)
Evidence-based recommendations on crovalimab (Piasky) for paroxysmal nocturnal haemoglobinuria in people 12 years and over.
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.
NICE is unable to recommend the use in the NHS of bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen. This is because Napp Pharmaceuticals did not provide an evidence submission.
Show all sections
Sections for TA206
NICE is unable to recommend the use in the NHS of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma. This is because Wyeth did not provide an evidence submission.
Show all sections
Sections for TA207
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin for treating chronic hepatitis C in adults.
Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)
Evidence-based recommendations on pazopanib (Votrient) for previously untreated advanced renal cell carcinoma in adults.
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)
Evidence-based recommendations on bendamustine for treating chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.
Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.